Global Information
회사소개 | 문의

중국의 발사르탄(Valsartan) 시장

Investigation Report on Chinese Valsartan Market, 2018-2022

리서치사 China Research and Intelligence
발행일 2018년 07월 상품 코드 296112
페이지 정보 영문 30 Pages
가격
US $ 2,200 ₩ 2,506,600 Unprintable PDF (Single User License)
US $ 3,300 ₩ 3,760,000 Printable & Editable PDF (Enterprisewide License)


중국의 발사르탄(Valsartan) 시장 Investigation Report on Chinese Valsartan Market, 2018-2022
발행일 : 2018년 07월 페이지 정보 : 영문 30 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

발사르탄(안지오텐 또는 디오반)은 안지오텐신 II 수용체 길항제(일반적으로 ARB 또는 안지오텐신 수용체 차단제로 불린다)로, 특히 1형 안지오텐신 수용체와의 높은 친화성을 가지고 있습니다. 발사르탄은 1996년에 FDA에 의해서 인가되었으며, 1998년에는 중국에서 Novartis에 의해 "Daiwen"이라는 상표명으로 등록되었습니다. 발사르탄 이후 Novartis는 발사르탄 복합조제를 개발하고 있습니다. 1997년 10월에 발사르탄/히드로클로로티아지드는 FDA에 의해 "CoDiovan"이라는 상표명으로 승인되었으며, 새롭게 개발된 암로디핀/발사르탄(Exforge)도 출시되었습니다. 발사르탄 최종 제품의 시장 점유율은 매년 85% 이상의 매출액을 차지하는 Novartis에 의해 점유되고 있습니다. 중국에서는 고혈압 환자가 2억명을 돌파할 것으로 예측됩니다.

중국의 발사르탄(Valsartan) 시장을 분석하고, 주요 제조업체의 시장 점유율, 중국 병원 시장의 가격 변화와 매출액, 주요 기업 및 시장 전망 등의 정보를 전해드립니다.

제1장 발사르탄 관련 개념

  • 적응증
  • 세계 시장의 판매 상황

제2장 중국의 발사르탄 시장 개요

  • 특허 상황
  • 주요 제조업체
  • 시장 규모

제3장 중국의 발사르탄 매출액 조사

  • 총매출액
  • 매출액 : 지역별

제4장 중국 주요 발사르탄 제조업체의 시장 점유율 조사

  • 시장 점유율 : 매출액별
  • 시장 점유율 : 매출량별

제5장 발사르탄 시장 규모 조사 : 중국의 투약 형태별

  • 시장 점유율 : 매출액 및 투약 형태별
  • 시장 점유율 : 매출액 및 투약 형태별

제6장 중국 병원 시장의 발사르탄 준거 가격

  • Tianda Group
  • Livzon Pharmaceutical Factory of Livzon Group
  • Beijing Novartis Pharma Co., Ltd.
  • Beijing Saike Pharmaceutical Co., Ltd.
  • Guilin Winsun Pharmaceutical Co., Ltd.
  • Changzhou Siyao Pharmaceutical Co., Ltd.
  • Hainan Bright Future Pharmaceutical Co.,Ltd.
  • Hainan Hualon Pharmaceutical Co., Ltd.

제7장 중국의 주요 발사르탄 제조업체 분석

  • Beijing Novartis
  • Beijing Saike
  • Changzhou Siyao
  • Hainan Hualon
  • Lunan Better

제8장 중국의 발사르탄 시장 전망

  • 시장 규모 예측
  • 경쟁 패턴 예측

주요 차트

KSM 14.03.04

Description

Valsartan is an angiotensin II receptor antagonist which blocks the angiotensin II receptor type I (AT1), increases the plasma level of angiotensin II, stimulates unblocked AT2 receptor, and counteracts the effects of AT1 receptor to dilate blood vessels and lower blood pressure. Valsartan tablets are mainly used to treat mild to moderate primary hypertension.

The growing economy has greatly changed the life style and diet of Chinese people and led to the increasing incidence of hypertension in China. According to population size and structure, China has over 300 million hypertensive patients, over 1/3 of the global total. However, China has a wide gap with developed countries on hypertension control rate. The new edition of List of Medicines Covered by National Basic Medical Insurance contains 271 cardiovascular drugs including 144 Chinese and western drugs and 127 Chinese patent drugs. It's worth mentioning that there are 6 cardiovascular drugs among the 36 drugs included in the list in 2017 after the second government-enterprise negotiation.

According to CRI, the sales value of Valsartan was about CNY 537 million in 2017, a slight decrease over 2016. The sales volume increased while the average price fell, which doesn't mean shrinking market demand.

There are many Valsartan manufacturers in China while the concentration ratio is high. In 2017, over 90% market share by sales value was captured by Beijing Novartis Pharma Co., Ltd., Lunan Better Pharmaceutical Co., Ltd., Novartis and Changzhou Siyao Pharmaceutical Co., Ltd. The Valsartan (trade name: Diovan) produced by Beijing Novartis Pharma Co., Ltd. took up over 85% of the Chinese market, and the domestic enterprises also gained some market share by price advantage. Many domestic pharmaceutical enterprises expect to scrabble for market shares from Novartis by advantage of lower prices. For example, in June 2018, Zhejiang Huahai Pharmaceutical Co., Ltd. obtained the production permit for Valsartan tablets (40mg, 80mg and160mg) from CFDA.

It is estimated that the incidence of hypertension and the demand for Valsartan will continue to grow in China in the coming years.

Topics Covered:

  • Development environment of Valsartan in China
  • Sales of Valsartan in China, 2013-2017
  • Market share of major Valsartan manufacturers in China
  • Sales of Valsartan in different dosage forms in China
  • Average price of Valsartan in China
  • Average prices of major manufacturers' Valsartan in China
  • Prospects of Chinese Valsartan market

Table of Contents

1 Relevant Concepts of Valsartan

  • 1.1 Indications for Valsartan
  • 1.2 Development History of Valsartan in China
  • 1.3 Production Permit of Valsartan in China

2 Investigation on Sales of Valsartan in China, 2013-2017

  • 2.1 Sales Value of Valsartan
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value in Different Regions
  • 2.2 Sales Volume of Valsartan
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume in Different Regions
  • 2.3 Sales of Valsartan in Different Dosage Forms in China
    • 2.3.1 Capsules
    • 2.3.2 Tablets

3 Market Shares of Major Valsartan Manufacturers in China, 2013-2017

  • 3.1 Market Shares of Major Valsartan Manufacturers in China
    • 3.1.1 Market Shares by Sales Value
    • 3.1.2 Market Shares by Sales Volume
  • 3.2 Beijing Novartis Pharma Co., Ltd.
    • 3.2.1 Profile of Beijing Novartis
    • 3.2.2 Sales of Beijing Novartis' Valsartan
  • 3.3 Lunan Better Pharmaceutical Co., Ltd.
  • 3.4 Novartis
  • 3.5 Changzhou Siyao Pharmaceuticals Co., Ltd.
  • 3.6 Hainan Hualon Pharmaceutical Co., Ltd.
  • 3.7 China Resources Saike Pharmaceutical Co., Ltd.

4 Analysis on Valsartan Prices in China, 2017-2018

  • 4.1 Price Overview
    • 4.1.1 Average Price
    • 4.1.2 Prices of Valsartan in Different Dosage Forms
  • 4.2 Prices of Valsartan of Different Enterprises
    • 4.2.1 Beijing Novartis Pharma Co., Ltd.
    • 4.2.2 Lunan Better Pharmaceutical Co., Ltd.
    • 4.2.3 Novartis
    • 4.2.4 Changzhou Siyao Pharmaceuticals Co., Ltd.
    • 4.2.5 Hainan Hualon Pharmaceutical Co., Ltd.
    • 4.2.6 China Resources Saike Pharmaceutical Co., Ltd.

5 Prospects of Chinese Valsartan Market, 2018-2022

  • 5.1 Forecast on Market Size
  • 5.2 Forecast on Competition Pattern

Selected Charts

  • Chart Valsartan Products Approved to Market in China by 2018
  • Chart Sales Value of Valsartan in China, 2007-2017
  • Chart Sales Value of Valsartan Capsules in China, 2013-2017
  • Chart Sales Value of Valsartan Tablets in China, 2013-2017
  • Chart Market Shares of Valsartan Enterprises by Sales Value in China, 2013-2017
  • Chart Profile of Beijing Novartis Pharma Co., Ltd.
  • Chart Sales of Beijing Novartis's Valsartan, 2013-2017
  • Chart Prices of Beijing Novartis's Valsartan in Different Regions of China, 2017-2018
  • Chart Sales Value of Valsartan in China, 2013-2017
  • Chart Forecast on Size of Chinese Valsartan Market, 2018-2022
Back to Top
전화 문의
이용안내
 
BCC Research